Programmatic Partnerships

We are a founding member of CARER, which is shining a spotlight on diversity in clinical trials.

We partner with the Davos Alzheimer Collaborative (recently expanded to include the Aga Khan Hospital in Nairobi, Kenya) to design and run the first Alzheimer’s clinical trial in Africa. RSV is providing shelved drug material to be used in the clinical trial, assistance in designing the clinical trial, and digital health expertise to identify and engage partners that can expand the trial to Africans with smartphone access, but limited access to hospitals.

We incubated Encora, an MIT-founded startup that has built a device to reduce hand tremors for those living with Parkinson’s Disease.

We co-founded the Global Gene Therapy Initiative, an international working group dedicated to expanding access to gene therapies for HIV and sickle cell disease in low and middle income countries.

We have partnered with Med Aditus to provide their team with two Global Access Fellowship placements to date. Med Aditus is working to build a sustainable ecosystem to produce and distribute affordable quality medicines for underserved patients in Sub-Saharan Africa.

We have partnered with SBP to launch a real-world training program that aims to accelerate therapeutic innovation by prioritizing unmet medical needs, engaging underserved populations, and training students from diverse backgrounds.

Medicine anywhere, anytime, for everyone. Sunflower’s technologies enable flexible, modular manufacturing of vaccines and proteins, including insulin. They can be used across the globe, including in low-and-middle-income countries.

We are collaborating with the Vanderbilt Institute for Clinical and Translational Research (VICTR) in developing therapies for traditionally underserved populations and diseases. Our multidisciplinary teams will seek to identify novel indications for existing medications, particularly generic or shelved compounds. By focusing on compounds with established safety and regulatory records, VICTR and RSV aim to bring treatments to market faster and more affordably. Notably, VICTR and RSV will also incorporate concrete commitments to data transparency, clinical trial diversity, and global affordable access in low- and middle-income countries (LMICs) directly into the framework of their collaboration.

In 2023 RSV launched the "Making Medicines" course at the UNC Eshelman School of Pharmacy, the top ranked School of Pharmacy in the United States. The course is designed to teach PharmD students to understand and appreciate the new drug approval process and key issues in drug discovery, pre-clinical testing, clinical trials, FDA approval, and global access to medicines. ”Making Medicines is taught by taught by Lindsay Androski, RSV Founder & CEO, and Scott Singleton, Associate Professor at the UNC Eshelman School of Pharmacy.

In May of 2023 Roivant Sciences and Roivant Social Ventures partnered to launch our inaugural Diversity in Pharma Internship Program, providing real-world drug development experience to these qualified PharmD students from diverse backgrounds. By increasing racial and gender diversity in future leaders of the biopharma industry, we can start to dismantle these inequities.